Abstract | BACKGROUND: METHODS: We performed an economic analysis of this trial from the US perspective using hospital bills and Medicare physician fees to estimate costs for cardiovascular hospitalizations in all US patients (n = 5,308). Atorvastatin costs were assigned using a discounted average wholesale price. Cost-effectiveness was calculated as the within-trial incremental cost required to prevent one primary end point event with high-dose atorvastatin. RESULTS: During a mean 4.9-year follow-up, the high-dose arm had fewer potential end point cardiovascular hospitalizations (35% vs 41%, P < .001) and revascularization procedures (16% vs 22%, P < .001). The high-dose regimen was $1 per day more expensive. At the end of 5 years, cumulative incremental cost for the high-dose arm was $252 (95% CI-$722 to +$1,276). With an absolute reduction in the primary end point of 2.8 per 100 treated with the high-dose regimen, the cost to prevent one additional primary end point event was $8,964. CONCLUSION:
|
Authors | Daniel B Mark, J David Knight, Patricia A Cowper, Linda Davidson-Ray, Kevin J Anstrom |
Journal | American heart journal
(Am Heart J)
Vol. 156
Issue 4
Pg. 698-705
(Oct 2008)
ISSN: 1097-6744 [Electronic] United States |
PMID | 18926150
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Heptanoic Acids
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Pyrroles
- Atorvastatin
|
Topics |
- Aged
- Atorvastatin
- Coronary Artery Disease
(drug therapy, economics, therapy)
- Female
- Heptanoic Acids
(administration & dosage, economics)
- Hospital Costs
- Hospitalization
(economics)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(administration & dosage, economics)
- Male
- Medicare
(economics)
- Middle Aged
- Myocardial Revascularization
(economics, statistics & numerical data)
- Outcome Assessment, Health Care
- Prospective Studies
- Pyrroles
(administration & dosage, economics)
- United States
|